The FDA adverse-event record for tiger

Tiger Adverse Event Insights

The FDA Center for Veterinary Medicine database holds 6 adverse event reports for Tiger, distributed across 0 distinct breeds currently tracked in the system. Of those reports, 2 involved a death outcome, producing a 33.3% case-fatality rate among reported events, which reflects reporting severity bias rather than true population mortality. These figures are aggregated directly from openFDA's Animal & Veterinary Adverse Events endpoint and update as new voluntary submissions flow through pet owners, veterinarians, and drug manufacturers.

The most frequently reported clinical signs for Tiger are Other abnormal test result NOS (3 reports), Abnormal ECG (2 reports), Hyperkalaemia (2 reports), Lethargy (see also Central nervous system depression in 'Neurological') (2 reports), with Other abnormal test result NOS leading the reaction traffic at 3 submissions. On the product side, Ketamine Hydrochloride is the single most-referenced drug with 2 reports, followed by Atipamezole Hydrochloride (2), Dexmedetomidine Hydrochloride (2), Isoflurane (1). This combination surfaces which therapeutic classes generate the most adverse event chatter for this species, a useful starting point when comparing Tiger reporting patterns against other companion animals in the dataset.

Of the 6 Tiger reports with a coded outcome, Recovered/Normal accounts for the largest share at 66.7%. Annual submission volume spans 2,014 to 2,020 reports across the 5 years on file, a range that reflects evolving owner awareness, veterinary reporting habits, and new product approvals rather than stable underlying incidence. The breed-level table below breaks these patterns down further, showing how the 0 tracked tiger breeds compare on volume, deaths, and average age at report. As with all FDA adverse event data, correlation is the ceiling, causation requires clinical investigation beyond what these aggregates can provide.